LTI Receives Funding for Research Aimed at Delaying or Preventing Parkinsonís Disease

(February 4, 2015) – Cambridge based Lysosomal Therapeutics Inc. (LTI) believes that that Parkinson's can be linked to the same kind of lysosomal storage disorder behind Gaucher's disease. LTI will also be working on a biomarker program that can clearly identify low levels of the lysosomal enzyme glucocerebrosidase that they believe is a likely trigger for the disease. If LTI is right, their drug could one day be used much like the way cholesterol drugs are applied to patients at risk of heart disease. Read more…